Lithium therapy: from clinical trials to practical management.

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Medicine

Background:

• Recurrent affective disorders, including unipolar, bipolar, and schizoaffective illnesses, are associated with significant morbidity.
• Lithium is an established mood stabilizer, but its efficacy in low-dose, once-daily regimens for ongoing affective morbidity requires further investigation.

Purpose of the Study:

• To evaluate the effectiveness of low-dose, once-daily lithium, supplemented with other medications as needed, in managing ongoing affective morbidity.
• To assess treatment efficacy across different affective disorder subtypes and age groups.

Main Methods:

• A cohort of patients with unipolar, bipolar, and schizoaffective disorders received low-dose, once-daily lithium.
• Medication was supplemented with antidepressants or neuroleptics as necessary.
• Affective morbidity was assessed over a one-year study period.
• Patients were categorized by age (older vs. younger) and subtype of unipolar depression (endogenous vs. nonendogenous).

Main Results:

• Seventy-eight percent of unipolar patients and 73% of bipolar and schizoaffective patients experienced no or only slight morbidity.
• The treatment demonstrated equal effectiveness in older (over 70 years) and younger patients.
• Endogenous unipolar patients showed significantly lower morbidity compared to nonendogenous patients.
• Subjective side effects were minimal.

Conclusions:

• Low-dose, once-daily lithium, combined with judicious use of other psychotropic medications, is an effective strategy for reducing ongoing morbidity in recurrent affective disorders.
• This treatment approach offers considerable benefit and is well-tolerated across different patient demographics, including the elderly.
• Regular clinical supervision is crucial for optimizing outcomes in patients with affective disorders.